BCM
DPLO

Bayesian Capital Management’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Bayesian Capital Management’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,400
Closed -$243K – 707
2017
Q2 		$243K Buy
16,400
+4,300
+36% +$71.7K 0.09% 337
2017
Q1 		$193K Buy
+12,100
New +$175K 0.09% 356

Other funds holding DPLO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIM
Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's DPLO Position: Q3 2017 in Review

Bayesian Capital Management sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q3 2017, closing a stake of 16,400 shares — an estimated $243K sold.

Bayesian Capital Management first reported a position in DPLO in Q1 2017 and held it in 2 quarters. The position peaked at $243K in Q2 2017. 165 funds tracked by Wall St. Rank hold DPLO as of Q3 2017.

  • Bayesian Capital Management reported no remaining DIPLOMAT PHARMACY, INC. position as of Q3 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 16,400 DIPLOMAT PHARMACY, INC. shares in Q3 2017, an estimated $243K.
  • Bayesian Capital Management first reported a position in DIPLOMAT PHARMACY, INC. in Q1 2017 and held it in 2 quarters.
  • Bayesian Capital Management's DIPLOMAT PHARMACY, INC. position peaked at $243K in Q2 2017.
  • 165 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q3 2017.

Based on Bayesian Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.